KR20200038115A - Composition for improving skin comprising natural material extract - Google Patents
Composition for improving skin comprising natural material extract Download PDFInfo
- Publication number
- KR20200038115A KR20200038115A KR1020180117818A KR20180117818A KR20200038115A KR 20200038115 A KR20200038115 A KR 20200038115A KR 1020180117818 A KR1020180117818 A KR 1020180117818A KR 20180117818 A KR20180117818 A KR 20180117818A KR 20200038115 A KR20200038115 A KR 20200038115A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- composition
- present
- ppm
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 94
- 239000000284 extract Substances 0.000 title claims abstract description 73
- 239000005445 natural material Substances 0.000 title description 2
- 230000000694 effects Effects 0.000 claims abstract description 44
- 239000002537 cosmetic Substances 0.000 claims abstract description 31
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 30
- 230000037303 wrinkles Effects 0.000 claims abstract description 28
- 230000037394 skin elasticity Effects 0.000 claims abstract description 26
- 230000036560 skin regeneration Effects 0.000 claims abstract description 24
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 108010035532 Collagen Proteins 0.000 claims abstract description 18
- 102000008186 Collagen Human genes 0.000 claims abstract description 18
- 229920001436 collagen Polymers 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 18
- 102000016387 Pancreatic elastase Human genes 0.000 claims abstract description 15
- 108010067372 Pancreatic elastase Proteins 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 230000005764 inhibitory process Effects 0.000 claims abstract description 15
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 13
- 230000004663 cell proliferation Effects 0.000 claims abstract description 11
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 11
- 230000009467 reduction Effects 0.000 claims abstract description 8
- 230000006872 improvement Effects 0.000 claims description 32
- 241000219061 Rheum Species 0.000 claims description 25
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims description 25
- 230000002087 whitening effect Effects 0.000 claims description 25
- 241000283690 Bos taurus Species 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 230000003020 moisturizing effect Effects 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 14
- 238000006206 glycosylation reaction Methods 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 239000003921 oil Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 230000005808 skin problem Effects 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000000344 soap Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- 238000003287 bathing Methods 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 11
- 240000005546 Piper methysticum Species 0.000 abstract description 3
- 235000016787 Piper methysticum Nutrition 0.000 abstract description 3
- 240000004980 Rheum officinale Species 0.000 abstract description 3
- 235000008081 Rheum officinale Nutrition 0.000 abstract description 3
- 244000306301 Caesalpinia sappan Species 0.000 abstract description 2
- 235000015162 Caesalpinia sappan Nutrition 0.000 abstract description 2
- 235000011783 Cedrela sinensis Nutrition 0.000 abstract description 2
- 241001078983 Tetradium ruticarpum Species 0.000 abstract description 2
- 206010040829 Skin discolouration Diseases 0.000 abstract 2
- 241001274614 Cynips Species 0.000 abstract 1
- 241001096414 Potentilla kleiniana Species 0.000 abstract 1
- 241000425037 Toona sinensis Species 0.000 abstract 1
- 230000001133 acceleration Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 92
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 22
- 239000002904 solvent Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 17
- 235000006708 antioxidants Nutrition 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- 230000036541 health Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- -1 pack Substances 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000008103 glucose Substances 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000036252 glycation Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000012422 Collagen Type I Human genes 0.000 description 4
- 108010022452 Collagen Type I Proteins 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 229910052750 molybdenum Inorganic materials 0.000 description 4
- 239000011733 molybdenum Substances 0.000 description 4
- 239000008055 phosphate buffer solution Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 2
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000218645 Cedrus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000004613 Pseudoxanthoma elasticum Diseases 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 229960003471 retinol Drugs 0.000 description 2
- 235000020944 retinol Nutrition 0.000 description 2
- 239000011607 retinol Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000010865 sewage Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 244000271246 Cedrela sinensis Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 241000269381 Cynops Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 229940122858 Elastase inhibitor Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000219428 Fagaceae Species 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000040141 Potentilla sundaica Species 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- 240000003829 Sorghum propinquum Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000736816 Xanthorhiza Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 108010056686 glycosylated collagen Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 235000005679 goldenseal Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- AJDUTMFFZHIJEM-UHFFFAOYSA-N n-(9,10-dioxoanthracen-1-yl)-4-[4-[[4-[4-[(9,10-dioxoanthracen-1-yl)carbamoyl]phenyl]phenyl]diazenyl]phenyl]benzamide Chemical group O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2NC(=O)C(C=C1)=CC=C1C(C=C1)=CC=C1N=NC(C=C1)=CC=C1C(C=C1)=CC=C1C(=O)NC1=CC=CC2=C1C(=O)C1=CC=CC=C1C2=O AJDUTMFFZHIJEM-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 239000003129 oil well Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940069514 rhubarb preparation Drugs 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000001043 yellow dye Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물을 유효성분으로 포함하는 화장료 조성물, 식품 조성물 또는 의약외품 조성물에 관한 것이다.The present invention relates to a cosmetic composition, a food composition or a quasi-drug composition comprising as an active ingredient a glutinous, bovine, rhubarb, osuyu, ohpilcho, hyangchunja or kawa extract.
구체적으로, 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물을 유효성분으로 포함하는 항산화용; 피부 보습용; 피부 미백용; 피부 트러블 개선용; 주름 개선용; 피부 탄력 증진용; 또는 피부 재생용 조성물에 관한 것이다. Specifically, for anti-oxidation, including molybdenum, bovine, rhubarb, osuyu, ohpilcho, hyangchunja or Kawa extract as an active ingredient; For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or it relates to a composition for skin regeneration.
피부는 연령의 증가 또는 자외선, 외부 오염 물질 및 스트레스에 의해 점점 손상되고 이러한 요인들로부터 피부를 보호하는 기능이 약화됨으로써, 세포 보호 및 증식 능력이 떨어진다. 이 경우 우리 몸은 손상된 피부에 대하여 피부 재생 과정을 시작한다. 피부 재생은 손상에 대한 조직의 반응이며 조직 회복의 과정으로, 피부가 손상된 후 2일부터 3주까지 지속된다. 이 시기에 섬유아세포는 콜라겐을 축적시켜 손상된 피부의 흠을 채우고, 섬유아세포의 증식을 유도하며, 상처부위에서는 새로운 세포와 간질성분의 재구성이 일어난다. Skin is increasingly damaged by age or by ultraviolet, external contaminants and stress, and the ability to protect the skin from these factors is weakened, resulting in poor cell protection and proliferation. In this case, the body begins the process of skin rejuvenation against damaged skin. Skin regeneration is the tissue's response to damage and is the process of tissue recovery, which lasts from 2 days to 3 weeks after the skin is damaged. At this time, fibroblasts accumulate collagen to fill the blemishes of damaged skin, induce proliferation of fibroblasts, and reconstruction of new cells and interstitial components in the wound site.
최근 환경오염으로 인한 자외선 양의 증가, 서구화된 생활습관, 스트레스 등 피부건강을 위협하는 요인들이 증가하고 있다. 이들은 피부 오염, 건조, 트러블, 피부면역체계 이상 등을 유발하며, 결국 피부염, 거칠음, 급격한 노화 등을 야기한다. Recently, factors that threaten skin health such as an increase in the amount of ultraviolet rays due to environmental pollution, westernized lifestyle, and stress are increasing. These cause skin contamination, dryness, trouble, skin immunity system abnormalities, and eventually dermatitis, roughness, and rapid aging.
특히, 체내 활성 산소종의 농도를 증가시키고, 이러한 활성 산소종은 세포구성 성분들인 지질, 단백질, 당 및 DNA 등을 공격하여 과산화 반응을 일으킴으로써 피부의 노화를 촉진하는 문제가 있다. 이에 따라, 활성 산소종의 생성을 억제하는 항산화 효과, 이를 통한 항노화(피부 노화 방지) 효과를 가지는 화장료 조성물에 대한 개발이 요구되고 있다.In particular, the concentration of free radicals in the body is increased, and these free radicals attack the cellular components of lipids, proteins, sugars, and DNA, thereby causing a peroxidation reaction, thereby promoting skin aging. Accordingly, there is a need to develop a cosmetic composition having an antioxidant effect that inhibits the generation of free radicals and an anti-aging (anti-aging) effect.
사람의 피부색은 멜라노사이트(melanocyte)의 활동성, 혈관의 분포, 피부의 두께, 인체 내외의 색소 함유 유무 등 여러 요인들에 의해 결정되며, 특히 멜라노사이트에서 타이로시나제(tyrosinase) 등의 효소가 작용하여 생성되는 멜라닌이라는 흑색 색소가 중요하다. 멜라닌은 피부에 존재하여 자외선 등으로부터 신체를 보호하는 중요한 기능을 하지만, 과잉생산될 경우 색소침착 및 피부노화를 촉진하고 피부암 유발에도 주요한 작용을 하는 것으로 알려져 있다.Human skin color is determined by a number of factors, including the activity of melanocytes, the distribution of blood vessels, the thickness of the skin, and the presence or absence of pigments inside and outside the human body.In particular, enzymes such as tyrosinase in melanocytes The black pigment called melanin produced by action is important. Melanin is present in the skin and plays an important function of protecting the body from ultraviolet rays, but when over-produced, it is known to promote pigmentation and skin aging and play a major role in inducing skin cancer.
과도한 멜라닌 색소 침착을 치료 또는 경감시켜주기 위해서, 이전부터 아스코르빈산(ascorbic acid), 코지산, 알부틴(arbutin), 하이드로퀴논(hudroquinone), 글루타치온(glutathione), 타이로시나제 저해활성을 가진 물질들을 화장료나 의약품에 배합하여 사용하였다. 그러나, 이들은 불충분한 미백 효과, 피부에 대한 안전성 문제, 화장료에 배합시 안정성 문제 등으로 인해 그 사용이 제한되고 있다.Substances with ascorbic acid, kojic acid, arbutin, hydroquinone, glutathione, and tyrosinase inhibitory activity to treat or alleviate excessive melanin pigmentation These were used in combination with cosmetics and medicines. However, their use is limited due to insufficient whitening effects, safety problems for the skin, and stability problems when blended in cosmetics.
한편, 피부 보호를 위해 화장품을 사용하게 되는데, 계면활성제, 방부제, 향료, 자외선 차단제, 색소 등 다양한 성분들이 피부에 염증이나 뾰루지, 부종 등 각종 트러블을 발생시키는 것으로 알려져 있다(Maibach. H. I., Contact Dermatitis, 6. 369-404, 1980). 또한, 태양으로부터 나오는 자외선에 의해서도 피부 염증이 유발되는 것으로 알려져 있으며, 체내로부터 배출되는 피지, 땀, 화장품 성분 중의 지방산, 단백질 등이 피부에 존재하는 피부 상재균에 의해 독성이 강한 물질로 분해됨으로써 피부 염증이 유발될 수도 있다. On the other hand, cosmetics are used to protect the skin, and various ingredients such as surfactants, preservatives, fragrances, sunscreens, and pigments are known to cause various problems such as inflammation, rash, and edema on the skin (Maibach. HI, Contact Dermatitis) , 6. 369-404, 1980). In addition, it is known that skin inflammation is caused by ultraviolet rays from the sun, and skin, as the sebum, sweat, fatty acids, and proteins in the cosmetic components discharged from the body are decomposed into highly toxic substances by the skin bacterial flora present on the skin. Inflammation may also be caused.
염증 반응은 세균과 같은 외부 물질의 침입과 기계적 손상으로부터 생체를 보호하려는 생리적인 반응으로서, 붉어짐, 따끔거림, 화끈거림, 팽윤, 조직의 변화 등의 현상을 유발하여, 인접한 조직 세포와 비세포 성분들에 해로운 손상을 일으키기도 한다. 따라서, 염증 유발 요인이 없어지지 않을 경우, 결과적으로 만성 염증이 일어나게 되어 더욱더 심각한 조직의 손상을 가져온다. 이에 따라, 항염증 효과를 통해 피부 트러블을 초기에 억제할 수 있는 화장료 조성물의 개발이 절실하다.Inflammatory reaction is a physiological reaction to protect the living body from the invasion and mechanical damage of foreign substances such as bacteria, and causes phenomena such as redness, tingling, burning, swelling, and tissue changes. It can also cause harmful damage to the fields. Therefore, if the inflammation-inducing factor is not eliminated, chronic inflammation occurs as a result, resulting in even more serious tissue damage. Accordingly, there is an urgent need to develop a cosmetic composition capable of initially suppressing skin troubles through anti-inflammatory effects.
콜라겐은 피부의 섬유아세포(fibroblast)에서 생성되는 주요 기질 단백질로서, 피부의 기계적 견고성과 조직의 결합력을 유지하고, 세포접착의 지탱, 세포 분화의 유도 등의 기능을 한다. 연령 증가 및 자외선 조사에 의한 광노화에 의해 콜라겐은 감소하며, 콜라겐을 분해하는 콜라게나제 효소 활성으로 콜라겐 감소가 촉진된다. 이는 피부의 주름 형성과도 밀접한 연관이 있다고 알려져 있다. Collagen is a major matrix protein produced in fibroblasts of the skin, and maintains the mechanical firmness of the skin and the cohesion of tissues, supports cell adhesion, and induces cell differentiation. Collagen decreases with age and photoaging by ultraviolet irradiation, and collagen reduction is accelerated by collagenase enzyme activity that breaks down collagen. This is known to be closely related to the formation of wrinkles on the skin.
또한, 엘라스틴(elastin)은 진피에 있는 섬유성분 가운데 비교적 적은 부분을 차지하고 있으며, 피부, 허파 및 혈관에 탄성력을 갖게 한다고 알려져 있고, 엘라스틴의 위축으로 인해 탄성섬유성 위황색종(PXE :pseudoxanthoma elasticum)이 발생하면 피부 탄력성이 감소한다고 알려져 있다.In addition, elastin occupies a relatively small portion of the fiber components in the dermis, and is known to have elasticity on skin, lungs, and blood vessels, and elastic fibrous gastric yellow tumor (PXE: pseudoxanthoma elasticum) due to atrophy of elastin. It is known that skin elasticity decreases when this occurs.
현재, 주름 개선 또는 피부 탄력 증진 화장료로는 레티놀, 아데노신, 클로렐라 추출물 등이 알려져 있다. 레티놀은 콜라겐 합성을 촉진하며 엘라스타제 효소를 저해하는 물질이지만, 불안정하고 피부 적용시 자극, 발진 등의 안전성 문제로 사용량의 제한이 있으며, 클로렐라 추출물 등은 보습 효과가 미미하여 실질적으로 효과를 기대하기가 어렵다고 알려져 있다.Currently, retinol, adenosine, chlorella extract, etc. are known as cosmetic agents for improving wrinkles or enhancing skin elasticity. Retinol is a substance that promotes collagen synthesis and inhibits the elastase enzyme, but is unstable and has limited use due to safety problems such as irritation and rash when applied to the skin. Is said to be difficult.
또한, 신체 내부에서는 단백질이 가지는 단백질 또는 지방에 포도당 또는 과당과 같은 단순당이 공유결합을 형성하는 비효소적 반응이 발생하며, 이를 당화(glycation)라고 한다. 당화된 콜라겐은 진피층의 세포 외 기질에서 콜라겐이 적절한 구조를 형성하지 못하도록 함으로써 피부의 탄력을 잃게 하고 주름 생성을 촉진한다. 또한 당화로 인해 생성된 최종당화산물(Advanced glycation endproducts; AGEs)은 갈색 빛을 띠는 물질로써 피부 노화가 진행됨에 따라 진피층 상부에 쌓이고 피부에서 반사되는 반사 빛이 줄어들게 된다. 이에, 최종당화산물은 피부 노화가 진행됨에 따라 그 양이 늘어나게 되고 점차 얼굴빛이 노랗고 칙칙하게 만드는 물질 중 하나로 꼽히고 있다(Hiroshi, O. et al, Skin Research and Technology, 15, p. 496, 2009). In addition, a non-enzymatic reaction in which a simple sugar such as glucose or fructose forms a covalent bond occurs in the protein or fat of the protein in the body, and this is called glycation. Glycosylated collagen prevents collagen from forming an appropriate structure in the extracellular matrix of the dermal layer, thereby losing skin elasticity and promoting wrinkle formation. In addition, advanced glycation end products (AGEs) produced by saccharification are brownish substances that accumulate on the top of the dermal layer as the skin ages and the reflected light reflected from the skin decreases. Accordingly, the final glycation end product increases as the skin aging progresses, and is gradually regarded as one of the substances that make the face yellow and gray (Hiroshi, O. et al, Skin Research and Technology, 15, p. 496, 2009). .
당화를 억제하는 물질로 아미노구아니딘(Aminoguanidine), 피리독사민(Pyridoxamine), 아스피린(Aspirin) 등이 알려져 있으나, 이들 물질은 피부에 대한 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 효과를 기대할 수 없는 문제점이 있다.Aminoguanidine, Pyridoxamine, Aspirin, etc. are known as substances that inhibit glycation, but these substances have practical limitations due to limitations in use or insignificant effects due to safety problems with the skin. There is a problem that can not be expected.
상기와 같은 배경 하에, 상기와 같은 배경 하에, 본 발명자들은 천연에 존재하는 자원들 중 항산화, 피부 보습, 피부 미백, 피부 트러블 개선, 주름 개선, 피부 탄력 증진, 피부 재생 효과가 우수한 물질에 관하여 연구를 수행하였으며, 천연소재 7종의 추출물이 각각 항당화, 멜라닌 감소, 콜라겐 합성 촉진, 엘라스타제 활성 저해, 세포 증식 효과가 있음을 확인함으로써 본 발명을 완성하였다.Under the above background, under the above background, the present inventors have researched on substances having excellent antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement, and skin regeneration effect among natural resources. The present invention was completed by confirming that the extracts of 7 natural materials each have anti-glycosylation, melanin reduction, collagen synthesis promotion, elastase activity inhibition, and cell proliferation effects.
본 발명의 목적은 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물을 유효성분으로 포함하는 화장료 조성물을 제공하는 것이다.An object of the present invention is to provide a cosmetic composition comprising as an active ingredient, glutinous, bovine, rhubarb, Osuyu, Ohpilcho, Hyangchunja or Kawa extract.
구체적으로, 상기 추출물을 유효성분으로 포함하는 항산화용; 피부 보습용; 피부 미백용; 피부 트러블 개선용; 주름 개선용; 피부 탄력 증진용; 또는 피부 재생용 조성물을 제공하는 것이다.Specifically, antioxidant for containing the extract as an active ingredient; For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or to provide a composition for skin regeneration.
본 발명의 다른 목적은 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물을 유효성분으로 포함하는 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition comprising as an active ingredient, glutinous, bovine, rhubarb, osuyu, ohpilcho, hyangchunja or Kawa extract.
본 발명의 또 다른 목적은 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물을 유효성분으로 포함하는 의약외품 조성물을 제공하는 것이다.Still another object of the present invention is to provide a quasi-drug composition comprising as an active ingredient a glutinous, bovine, rhubarb, osuyu, opilcho, hyangchunja or kawa extract.
본 발명의 하나의 양태는 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물을 유효성분으로 포함하는 화장료 조성물을 제공한다.One aspect of the present invention provides a cosmetic composition comprising as an active ingredient, glutinous, bovine, rhubarb, osuyu, ohpilcho, hyangchunja or Kawa extract.
본 발명에 있어서, "몰식자(Cynips gallae - tinctoria, 沒食子)"는 너도밤나무과 식물의 어린 가지에 어리상수리혹벌이 산란하여 생긴 벌레혹으로서, 바깥면은 갈색이나 올리브 녹색으로 작은 돌기가 있으며 질은 단단하다. 몰식자산계 탄닌을 함유하여 주로 염료, 가죽무두질, 머리염색제, 잉크 재료 등에 사용된다. In the present invention, " Cynops gallae - tinctoria (沒 食 子) "is a worm hump produced by the spawning of a beech beetle on a young branch of a beech family. The outer surface is brown or olive green with small bumps and hard quality. Therefore, it is mainly used for dyes, leather tanning, hair dyes, and ink materials.
본 발명에 있어서, "소목(Caesalpinia sappan, 蘇木)"은 인도, 말레이시아, 중국 남부 등의 열대 아시아에 분포하는 콩과 상록교목으로서, 소방목, 적목, 홍자 등으로도 불린다. 적황색 목재 부분은 홍색계 염료로 쓰이고, 뿌리는 황색염료로 쓰인다. 구체적으로, 상기 나무의 심재(heartwood, 心材)를 이용한 약재를 의미할 수 있고, 이는 한방에서 항균제, 항염제, 진통제 등의 처방에 주로 사용되어 왔다.In the present invention, " Caesalpinia sappan , 蘇木) "is a soybean and evergreen tree distributed in tropical Asia such as India, Malaysia, and southern China. It is also called firewood, red-eye, and crimson. The red-yellow wood part is used as a red dye, and the root is a yellow dye. Specifically, it may mean a medicine using a heartwood (心 材) of the tree, which has been mainly used for prescription of antibacterial, anti-inflammatory, and analgesic drugs in oriental medicine.
본 발명에 있어서, "대황(Rheum officinale, 大黃)"은 마디풀과에 속하는 여러해살이풀로서, 전 세계에 분포하며 산골짜기의 습지에서 자란다. 굵은 황색 뿌리가 있고 줄기는 거칠며 속이 비어 있고 곧게 자란 원줄기의 높이는 1m에 달한다. 구체적으로, 약용대황(Rheum officinale Baillon)의 뿌리줄기를 사용하여 만든 약재를 의미할 수 있고, 이는 한방에서 변비, 코피, 이뇨, 부종 등의 치료에 주로 사용되어 왔다.In the present invention, "Rhuum ( Rheum officinale , 大黃)" is a perennial plant belonging to the family Nodaceae, which is distributed all over the world and grows in wetlands of valleys. It has thick yellow roots, rough stems, hollow, straight stems up to 1 m high. Specifically, it may mean a medicine made by using rhizomes of Rheum officinale Baillon, which has been mainly used for treatment of constipation, nosebleeds, diuresis, and edema in oriental medicine.
본 발명에 있어서, "오수유(Evodia rutaecarpa, 吳茱萸)"는 산초나무과 식물인 오수유나무의 성숙되지 않은 열매로서, 한방에서는 위를 따뜻하게 하고 통증을 멎게 하며 기의 순환을 조절하여 구토, 두통, 구내염, 치통 등의 치료에 주로 사용되어 왔다.In the present invention, "Sooyu ( Evodia rutaecarpa , 吳茱萸 ) "is the unripe fruit of the wild plant, the cypress, which has been used mainly in the treatment of vomiting, headache, stomatitis, toothache, etc. by warming the stomach, stopping pain, and controlling the circulation of the flag. .
본 발명에 있어서, "오필초(Potentilla kleiniana)"는 땅에 엎드려 사방으로 뻗어나는 여러해살이풀로서, 가락지나물, 사함, 위사, 지오가, 오성초 등으로도 부른다. 온몸에 잔털이 비스듬히 누워 있고, 밑동에서 갈라진 여러 대의 줄기는 50cm 정도의 높이로 자란다. 해열, 진해, 해독, 소종 등의 효능이 있어 한방에서는 해열제, 기침, 인후염 등의 치료약으로 사용되어 왔다.In the present invention, "O Pilcho ( Potentilla kleiniana ) "is a perennial plant lying on the ground and extending in all directions. It is also called Garaknamul , Saham , Weft , Geoga , Ohseongcho , etc. The hairs are lying at an angle on the body, and several stems split at the base are about 50cm long. It has the effect of antipyretic, antitussive, detoxification, and edema, so it has been used as a medicine for antipyretics, coughing and sore throat in oriental medicine.
본 발명에 있어서, "향춘자(Toona sinensis, 香椿子)"는 참죽나무의 열매를 의미하며, 9~10월에 길이 2.5cm 정도의 타원형의 삭과가 달려 다갈색으로 익는다. 한방에서는 감기, 류머티스 관절염 등의 치료를 위해 사용되어 왔다.In the present invention, "Hyangchunja ( Toona sinensis , 香椿 子) "means the fruit of the oak tree, ripening to dark brown with an oval shaped 2.5cm long stem from September to October. It has been used for the treatment of colds, rheumatoid arthritis, etc.
본 발명에 있어서, "가와(Piper methysticum, kava)"는 폴리네시아, 멜라네시아 및 미크로네시아 등지에서 발견되는 후추나무속의 관목으로서, Awa(하와이), Ava(사모아), Yagona(피지), Sakau(폰페이), 하마하마 또는 카바카바 등으로 알려져 있다. 구체적으로, 뿌리 부위를 의미할 수 있는데, 뿌리 부분으로부터 추출한 카바락톤의 경우 진정, 수면 유도, 마취 효과 등이 있는 것으로 알려져 있다. In the present invention, "Kawa ( Piper methysticum , kava)" is a black pepper shrub found in Polynesia, Melanesia, and Micronesia, such as Awa (Hawaii), Ava (Samoa), Yagona (Fiji), Sakau (Ponpei). , Hamahama or Kaaba Kaba. Specifically, it may mean a root region, and it is known that the carabalactone extracted from the root region has a sedative, sleep-inducing, and anesthetic effect.
본 발명에 있어서, "추출물"은 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와의 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. 상기 추출물은 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와의 천연, 잡종 또는 변종 식물로부터 추출될 수 있고, 식물 조직 배양물로부터도 추출이 가능하다.In the present invention, "extract" is an extract obtained by the extraction treatment of molybdenum, bovine, rhubarb, sorghum, opilcho, hyangchunja or kawa, dilution or concentrate of the extract, dried product obtained by drying the extract, the extract And extracts of all formulations that can be formed using the extract itself and the extract, such as a crude or purified product, or mixtures thereof. The extract may be extracted from natural, hybrid, or varietal plants of molluscs, cedar, rhubarb, oleander, opilcho, hyangchunja, or kawaii, and can also be extracted from plant tissue cultures.
본 발명에서 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물을 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 포함하며, 이들을 단독으로 수행하거나 2종 이상의 방법을 병용하여 수행할 수 있으나, 이에 제한되지 않는다.In the present invention, the method of extracting the extract of molybdenum, bovine, rhubarb, osuyu, opilcho, hyangchunja or kawa is not particularly limited, and may be extracted according to a method commonly used in the art. Hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method, and the like, these may be performed alone or in combination of two or more methods, but are not limited thereto.
본 발명에서 추출에 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해 기술분야에서 공지된 임의의 용매를 사용할 수 있다. 추출 용매로는 물(또는 증류수); 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 탄소수 1 내지 4의 저급 알코올; 글리세린, 부틸렌글리콜, 프로필렌글리콜 등의 다가 알코올; 및 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합물을 사용할 수 있으나, 이에 제한되지 않는다. 또한, 상기 용매를 사용하여 1회 이상 추출하여 용매 추출물을 제조할 수 있고, 상기 용매 추출물을 감압 증류한 후 동결건조 또는 분무 건조하여 얻은 건조 추출물을 제조할 수 있다.The type of the extraction solvent used for extraction in the present invention is not particularly limited, and any solvent known in the art may be used. The extraction solvent includes water (or distilled water); Lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propyl alcohol, and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; And hydrocarbon-based solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or a mixture of these may be used, but is not limited thereto. In addition, a solvent extract may be prepared by extracting one or more times using the solvent, and a dry extract obtained by distilling the solvent extract under reduced pressure and then freeze-drying or spray drying may be prepared.
본 발명의 일 실시예에서는 메탄올을 사용하여 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 및 가와 추출물을 제조한 후 이의 피부 개선 효능을 확인하였다.In an exemplary embodiment of the present invention, methanol was used to prepare a molar, bovine, rhubarb, osuyu, opilcho, hyangchunja, and kawaii extract, and then confirm its skin improvement efficacy.
본 발명에서 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물은 이의 분획물, 이의 가공물, 이를 포함하는 동·식물, 이의 추출물의 형태로 포함될 수 있다.In the present invention, the mole meal, bovine, rhubarb, osuyu, opilcho, hyangchunja or kawa extract may be included in the form of fractions thereof, processed products thereof, animals and plants containing them, and extracts thereof.
본 발명에 있어서, "분획물"은 여러 다양한 구성 성분들을 포함하는 혼합물로부터 특정 성분 또는 특정 성분 그룹을 분리하기 위하여 분획을 수행하여 얻어진 결과물을 의미한다.In the present invention, "fraction" means a result obtained by performing fractionation to separate a specific component or a specific component group from a mixture comprising various various constituents.
본 발명에서 분획물을 얻는 분획 방법은 특별히 제한되지 아니하며, 당해 기술분야에서 통상적으로 사용하는 방법에 따라 수행될 수 있다. 상기 분획 방법의 비제한적인 예로는, 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와를 추출하여 얻은 추출물에 소정의 용매를 처리하여 상기 추출물로부터 분획물을 얻는 방법이 있으나, 이에 제한되지 않는다.The fractionation method for obtaining a fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art. Non-limiting examples of the fractionation method include, but are not limited to, a method of obtaining a fraction from the extract by treating a predetermined solvent to an extract obtained by extracting molybdenum, cedar, rhubarb, osuyu, opilcho, hyangchunja, or kawa Does not.
상기 분획에 사용되는 용매의 종류는 특별히 제한되지 아니하며, 당해 기술분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 분획 용매로는 물, 알코올 등의 극성 용매; 헥산(Hexane), 에틸아세테이트(Ethyl acetate), 클로로포름(Chloroform), 디클로로메탄(Dichloromethane) 등의 비극성 용매를 사용할 수 있고, 이들을 단독으로 사용하거나 2종 이상 혼합하여 사용할 수 있으나, 이에 제한되지 않는다. The type of solvent used in the fraction is not particularly limited, and any solvent known in the art may be used. The fractional solvent includes polar solvents such as water and alcohol; Non-polar solvents such as Hexane, Ethyl acetate, Chloroform, and Dichloromethane may be used, and these may be used alone or in combination of two or more, but are not limited thereto.
구체적으로, 본 발명의 화장료 조성물은 항산화용; 피부 보습용; 피부 미백용; 피부 트러블 개선용; 주름 개선용; 피부 탄력 증진용; 또는 피부 재생용일 수 있다. Specifically, the cosmetic composition of the present invention is for antioxidant; For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or it may be for skin regeneration.
본 발명에 있어서, "항산화"란 세포 내 대사 또는 자외선의 영향으로 인한 산화적 스트레스에 따라 반응성이 높은 자유 라디칼(free radical) 또는 활성산소종(reactive oxygen species)에 의한 세포 산화를 억제하는 것을 의미하며, 자유 라디칼 또는 활성산소종을 제거하여 이로 인한 세포 손상이 감소하는 것을 포함한다.In the present invention, "antioxidation" means inhibiting cell oxidation by free radicals or reactive oxygen species, which are highly reactive according to oxidative stress due to the effects of metabolism or ultraviolet rays in cells. And removing free radicals or free radicals, thereby reducing cell damage.
본 발명에 있어서, "피부 보습"이란 피부에 수분감을 증가시켜주고, 촉촉한 상태를 유지시키는 것을 의미한다. 피부 보습 효과를 높일 경우 피부의 주름 개선, 탄력도 증가에도 이로운 영향을 미칠 수 있다.In the present invention, "skin moisturizing" means to increase the feeling of moisture on the skin and maintain a moist state. Increasing the skin moisturizing effect can have a beneficial effect on improving the wrinkles and increasing the elasticity of the skin.
본 발명에 있어서, "피부 미백"이란 멜라닌 색소의 합성을 저해함으로써 피부톤을 밝히고, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 의미한다. 이러한 미백 효과는 예를 들어, 멜라닌 색소 총량을 감소시킴으로써 달성될 수 있으나, 본 발명이 이러한 작용 기전에 제한되는 것은 아니다.In the present invention, the term “skin whitening” refers to lightening the skin tone by inhibiting the synthesis of melanin pigments and improving skin hyperpigmentation, such as ultraviolet rays, hormones or oil-induced freckles and freckles. This whitening effect can be achieved, for example, by reducing the total amount of melanin pigment, but the present invention is not limited to this mechanism of action.
본 발명에 있어서, "피부 트러블 개선"이란 피부에 트러블이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 트러블을 완화시키는 것을 의미하며, 항염증에 의해 달성될 수 있으나, 본 발명이 이러한 작용 기전에 제한되는 것은 아니다.In the present invention, "improve skin trouble" refers to inhibiting or inhibiting the generation of troubles on the skin, or alleviating the problems that have already been created, and can be achieved by anti-inflammatory, but the present invention is based on this mechanism of action. It is not limited.
상기 피부 트러블은 대식세포에서의 과도한 일산화질소 생성으로 인하여 유발된 염증에 의해 발생할 수 있는 피부질환을 의미한다. 염증과 관련된 피부질환이면 그 종류에 관계없이 모두 포함되며, 상기 염증과 관련된 피부질환은 아토피 피부염, 건선, 방사선, 화학물질, 화상 등에 의해 촉발되는 홍반성 질환, 산 화상, 수포성 피부병, 태선 모양 종류 질환, 알레르기에 기한 가려움증, 지루성 습진, 장미 여드름, 심상성 천포창, 다형 삼출성 홍반, 결절 홍반, 귀두염, 음문염, 원형 탈모증과 같은 염증성 모발 손실, 피부 T-세포 림프종 등을 포함하며, 구체적으로, 피부발진, 여드름, 뾰루지, 주사(빨간 코)일 수 있으나 이에 제한되지 않는다. The skin trouble refers to a skin disease that may be caused by inflammation caused by excessive nitrogen monoxide production in macrophages. If it is a skin disease related to inflammation, it is included regardless of its type, and the skin disease related to inflammation includes atopic dermatitis, psoriasis, radiation, chemicals, burns, erythematous diseases, acid burns, blistering skin diseases, and thyroid patterns Types of diseases, including itching due to allergies, seborrheic eczema, rose acne, vulgar erythema, polymorphic exudative erythema, nodular erythema, inflammatory hair loss such as glansitis, vulvitis, alopecia areata, skin T-cell lymphoma, etc. , Skin rash, acne, rash, injection (red nose), but is not limited thereto.
상기 항염증은 피부에서 발병된 염증을 억제하는 것을 의미하며, 이는 과도한 나이트릭 옥사이드(nitric oxide; NO) 생성을 억제함으로써 달성될 수 있다. 특히 본 발명의 조성물은 항염증 효과를 통해서 여드름과 같은 피부 트러블을 개선하는 효과를 가질 수 있다.The anti-inflammatory means inhibiting the inflammation developed in the skin, which can be achieved by inhibiting excessive nitric oxide (NO) production. In particular, the composition of the present invention may have an effect of improving skin trouble such as acne through the anti-inflammatory effect.
본 발명에 있어서, "주름 개선"이란 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 의미한다. In the present invention, "wrinkle improvement" refers to suppressing or inhibiting the formation of wrinkles on the skin, or to relieve wrinkles already created.
본 발명에 있어서, "피부 탄력 증진"이란 피부가 쳐지거나 늘어지는 정도를 완화시켜주는 것을 의미한다.In the present invention, "enhancing skin elasticity" It means to relieve the degree of sagging or sagging of the skin.
본 발명에 있어서, "피부 재생"이란 피부 외부 및 내부 원인에 의한 손상에 대하여 피부 조직이 회복되는 것을 의미한다. 상기 외부 원인에 의한 손상은 자외선, 외부 오염 물질, 창상, 외상 등을 들 수 있으며, 상기 내부 원인에 의한 손상은 스트레스 등을 들 수 있으나, 이에 제한되지 않는다.In the present invention, "skin regeneration" means that the skin tissue is restored against damage caused by external and internal causes of the skin. The damage caused by the external cause may include ultraviolet rays, external pollutants, wounds, trauma, etc., and the damage caused by the internal cause may include stress, but is not limited thereto.
구체적으로, 본 발명의 조성물은 항당화, 멜라닌 감소, 항염증, 콜라겐 합성 촉진, 엘라스타제 활성 저해, 세포 증식 효과를 가지는 것일 수 있다. 본 발명의 일 실시예에서는 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물이 각각 항산화 및 항당화 효과, 멜라닌 생성 저해 효과, NO 생성 억제 효과, 제1형 콜라겐(type Ⅰ collagen) 합성 촉진 효과, 엘라스타제 활성 저해 효과, 세포 증식 효과가 있어(표 1 내지 표 7), 항산화, 피부 보습, 피부 미백, 피부 트러블 개선, 주름 개선, 피부 탄력 증진 및/또는 피부 재생 용도로 유용하게 사용될 수 있음을 확인하였다.Specifically, the composition of the present invention may have anti-glycosylation, melanin reduction, anti-inflammatory, collagen synthesis promotion, elastase activity inhibition, cell proliferation effect. In one embodiment of the present invention, anti-oxidant and anti-glycosylation effects, melanin production inhibitory effect, NO production inhibitory effect, type 1 collagen, type 1 collagen Synthetic promoting effect, elastase activity inhibitory effect, cell proliferation effect (Table 1 to Table 7), antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement and / or skin regeneration use It was confirmed that it can be used.
본 발명의 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되지 않는다. The cosmetic composition of the present invention is a solution, ointment for ointment, cream, foam, nutrient cosmetic, soft cosmetic, pack, soft water, emulsion, makeup base, essence, soap, liquid detergent, bathing agent, sunscreen cream, sun oil, suspension, emulsion Liquid, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch and spray can be prepared in a formulation selected from the group consisting of, but not limited to .
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되지 않는다. 본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.In addition, the cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers formulated in general skin cosmetics, and for example, oils, water, surfactants, moisturizers, lower alcohols as common ingredients, Thickeners, chelating agents, pigments, preservatives, fragrances, etc. may be appropriately blended, but are not limited thereto. The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있으나, 이에 제한되지 않는다.When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures of these may be used, but are not limited thereto.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있으나, 이에 제한되지 않는다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, especially in the case of a spray, additional chloro Propellants such as fluorohydrocarbon, propane / butane or dimethyl ether, but are not limited thereto.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있으나, 이에 제한되지 않는다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-Butylglycol oil can be used, in particular cottonseed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan. However, it is not limited thereto.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있으나, 이에 제한되지 않는다.When the formulation of the present invention is a suspension, liquid diluents such as water, ethanol or propylene glycol as carrier components, suspensions such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, micro Crystalline cellulose, aluminum metahydroxide, bentonite, agar or trakant, etc. may be used, but are not limited thereto.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있으나, 이에 제한되지 않는다.When the formulation of the present invention is a soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars, etc. may be used as carrier components. However, it is not limited thereto.
본 발명의 다른 양태는 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물을 유효성분으로 포함하는 식품 조성물을 제공한다.Another aspect of the present invention provides a food composition comprising as an active ingredient, glutinous, bovine, rhubarb, osuyu, ohpilcho, hyangchunja or Kawa extract.
구체적으로, 본 발명의 식품 조성물은 항산화용; 피부 보습용; 피부 미백용; 피부 트러블 개선용; 주름 개선용; 피부 탄력 증진용; 또는 피부 재생용일 수 있다.Specifically, the food composition of the present invention is for antioxidant; For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or it may be for skin regeneration.
몰식자, 소목, 대황, 오수유, 오필초, 향춘자, 가와, 항산화, 피부 보습, 피부 미백, 피부 트러블 개선, 주름 개선, 피부 탄력 증진, 피부 재생은 상기에서 설명한 바와 같다.Informal, bovine, rhubarb, osuyu, ohpilcho, hyangchunja, kawa, antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement, skin regeneration are as described above.
상기 식품 조성물은 건강기능식품의 형태로 사용될 수 있으나, 이에 제한되지 않는다. 또한 본 발명의 식품 조성물은 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물 이외에 식품학적으로 허용 가능한 식품보조첨가제를 포함할 수 있다.The food composition may be used in the form of a health functional food, but is not limited thereto. In addition, the food composition of the present invention may include food additives, food additives, in addition to edible, bovine, rhubarb, miso, pilcho, hyangchunja or kawa extract.
본 발명에 있어서, "식품보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 통상의 기술자가 적절히 선택하여 사용할 수 있다. 식품보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 이에 제한되지 않는다.In the present invention, "food supplement additive" means a component that can be supplementally added to food, and is added to prepare a health functional food of each formulation, and can be appropriately selected and used by a person skilled in the art. Examples of food additives include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners , pH adjusting agents, stabilizers, preservatives, glycerin, alcohol, carbonic acid used in carbonated beverages, and the like.
본 발명의 식품 조성물에는 건강기능식품이 포함될 수 있다. 상기 건강식품이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 의미한다. 여기서 기능성이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 항산화, 피부 보습, 피부 미백, 피부 트러블 개선, 주름 개선, 피부 탄력 증진 또는 피부 재생 효과를 증진시키기 위한 보조제로 섭취가 가능하다.The food composition of the present invention may include a health functional food. The healthy food refers to food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills using ingredients or ingredients having useful functionality for the human body. Here, the term "functionality" means obtaining a useful effect for health use, such as adjusting nutrients or physiological effects on the structure and function of the human body. The health functional food of the present invention can be manufactured by a method conventionally used in the art, and may be prepared by adding raw materials and ingredients commonly added in the art. In addition, the formulation of the health functional food can also be prepared without limitation as long as the formulation is recognized as a health functional food. The food composition of the present invention can be manufactured in various types of formulations, and has the advantage of not having side effects that may occur when taking the drug for a long time by using food as a raw material, unlike general medicines, and is excellent in portability. Health functional foods can be consumed as supplements for antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement or skin regeneration effect.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용 가능하다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 추출물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한 동물을 위한 사료로 이용되는 식품도 포함한다.There is no limitation in the form that the health functional food of the present invention can take, it may include all foods in a common sense, and it is interchangeable with terms known in the art, such as functional food. In addition, the health functional food of the present invention can be prepared by mixing appropriate other auxiliary ingredients and known additives that may be included in the food according to the choice of those skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, dairy products including gums, ice cream, various soups, beverages, teas, drinks, alcoholic beverages, and There are vitamin complexes and the like, and can be prepared by adding the extract according to the present invention as a main component, and adding it to juice, tea, jelly, and juice. It also includes foods used as feed for animals.
본 발명의 또 다른 양태는 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물을 유효성분으로 포함하는 의약외품 조성물을 제공한다.Another aspect of the present invention provides a quasi-drug composition comprising as an active ingredient, glutinous, bovine, rhubarb, osuyu, opilcho, hyangchunja or Kawa extract.
구체적으로, 본 발명의 의약외품 조성물은 항산화용; 피부 보습용; 피부 미백용; 피부 트러블 개선용; 주름 개선용; 피부 탄력 증진용; 또는 피부 재생용일 수 있다. Specifically, the quasi-drug composition of the present invention is for antioxidant; For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or it may be for skin regeneration.
몰식자, 소목, 대황, 오수유, 오필초, 향춘자, 가와, 항산화, 피부 보습, 피부 미백, 피부 트러블 개선, 주름 개선, 피부 탄력 증진, 피부 재생은 상기에서 설명한 바와 같다.Informal, bovine, rhubarb, osuyu, ohpilcho, hyangchunja, kawa, antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement, skin regeneration are as described above.
본 발명의 의약외품 조성물에는 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물 이외에 필요에 따라 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더욱 포함할 수 있다. 상기 약학적으로 허용 가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다. The quasi-drug composition of the present invention may further include pharmaceutically acceptable carriers, excipients, or diluents, if necessary, in addition to edible, bovine, rhubarb, miso, filcho, or kawa extract. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not impair the effects of the present invention, for example, fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, lubricants, sweeteners, fragrances, preservatives, etc. It can contain.
본 발명의 약학적으로 허용 가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 포함할 수 있으나, 이에 제한되지 않는다. Representative examples of pharmaceutically acceptable carriers, excipients or diluents of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia rubber, alginate, calcium phosphate, calcium Carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil , Injectable ester, witepsol, macrogol, tween 61, cacao butter, laurid, and the like, but is not limited thereto.
본 발명의 의약외품 조성물은 소독 청결제, 샤워폼, 연고액, 물티슈, 코팅제 등을 예시할 수 있으나 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다.The quasi-drug composition of the present invention may be exemplified by disinfecting cleansers, shower foams, ointments, wipes, coatings, etc., but is not limited thereto, and formulation methods, dosages, methods of use, and components of quasi-drugs are generally known in the art. It can be appropriately selected from the technology.
본 발명의 화장료 조성물, 식품 조성물, 의약외품 조성물은 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 추가로 함유할 수 있다. 예컨대, 본 발명이 속한 기술분야에서 공지된 항산화, 피부 보습, 피부 미백, 피부 트러블 개선, 주름 개선, 피부 탄력 증진 및/또는 피부 재생 성분을 포함할 수 있을 것이다. 상기 추가 성분으로 인해, 본 발명의 조성물의 항산화, 피부 보습, 피부 미백, 피부 트러블 개선, 주름 개선, 피부 탄력 증진 및/또는 피부 재생 효과는 더욱 증진될 수 있을 것이다. 추가 성분의 함량 범위는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성 등을 고려하여 통상의 기술자가 적절히 조절할 수 있다.The cosmetic composition, food composition, and quasi-drug composition of the present invention may further contain one or more active ingredients exhibiting the same or similar functions. For example, it may include antioxidants, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement and / or skin regeneration ingredients known in the art. Due to the additional ingredients, the antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement and / or skin regeneration effect of the composition of the present invention may be further enhanced. The content range of additional ingredients may be appropriately adjusted by a person skilled in the art in consideration of skin safety according to the combined use, ease of formulation, and stability of active ingredients.
나아가, 본 발명은 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물을 개체의 피부에 도포하는 단계를 포함하는, 항산화; 피부 보습; 피부 미백; 피부 트러블 개선; 주름 개선; 피부 탄력 증진; 또는 피부 재생 방법을 제공한다. 상기 개체는 쥐, 가축, 인간 등을 포함하는 포유동물을 제한 없이 포함할 수 있다.Furthermore, the present invention comprises the step of applying a mosquito, bovine, rhubarb, Osu, Opilcho, Hyangchunja or Kawa extract to the skin of an individual, antioxidant; Skin moisturizing; Skin whitening; Skin trouble improvement; wrinkle improvement; Promoting skin elasticity; Or provide a method for skin regeneration. The individual may include, without limitation, mammals including rats, livestock, and humans.
본 발명의 조성물은 항당화, 멜라닌 감소, 항염증, 콜라겐 합성 촉진, 엘라스타제 활성 저해, 세포 증식 효과가 우수하여, 항산화, 피부 보습, 피부 미백, 피부 트러블 개선, 주름 개선, 피부 탄력 증진, 피부 재생 용도로 유용하게 사용될 수 있다. 따라서, 본 발명의 조성물은 피부에 안전하면서도 피부 상태 개선 효과가 우수한 화장료 조성물, 식품 조성물, 의약외품 조성물로 이용될 수 있다.The composition of the present invention has excellent anti-glycosylation, melanin reduction, anti-inflammatory, collagen synthesis promotion, elastase activity inhibition, cell proliferation effect, antioxidant, skin moisturizing, skin whitening, skin trouble improvement, wrinkle improvement, skin elasticity enhancement, It can be usefully used for skin regeneration. Therefore, the composition of the present invention can be used as a cosmetic composition, a food composition, and a quasi-drug composition that is safe for skin and has an excellent skin condition improving effect.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. These examples are intended to illustrate the present invention more specifically, but the scope of the present invention is not limited to these examples.
실시예Example 1: 몰식자 추출물의 제조 1: Preparation of extract from the molester
몰식자를 잘 건조하여 세절한 후, 건조 중량 100g을 플라스크에 넣고 추출 용매(70% MeOH) 3000g으로 70℃에서 3시간동안 추출하였다. 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과, 농축한 후 증류수에 1:10으로 용해하여 몰식자 추출물을 제조하였다.After drying and slicing well, the dry meal was put in a flask 100 g of dry weight and extracted at 70 ° C. for 3 hours with 3000 g of extraction solvent (70% MeOH). The extract was filtered through a filter having a pore size of 0.2 μm, concentrated, and dissolved in distilled water at 1:10 to prepare a molar extract.
실시예Example 2: 소목 추출물의 제조 2: Preparation of pine tree extract
소목을 잘 건조하여 세절한 후, 건조 중량 100g을 플라스크에 넣고 추출 용매(70% 메탄올) 3000g으로 70℃에서 3시간동안 추출하였다. 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과, 농축한 후 증류수에 1:10으로 용해하여 소목 추출물을 제조하였다.After drying and crushing the small well, 100 g of dry weight was placed in a flask and extracted with 3000 g of an extraction solvent (70% methanol) at 70 ° C. for 3 hours. The extract was filtered through a filter having a pore size of 0.2 μm, concentrated, and dissolved in distilled water at 1:10 to prepare a pine extract.
실시예Example 3: 3: 대황rhubarb 추출물의 제조 Preparation of extract
대황을 잘 건조하여 세절한 후, 건조 중량 100g을 플라스크에 넣고 추출 용매(70% 메탄올) 3000g으로 70℃에서 3시간동안 추출하였다. 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과, 농축한 후 증류수에 1:10으로 용해하여 대황 추출물을 제조하였다.After drying and rinsing the rhubarb well, 100 g of dry weight was placed in a flask and extracted with 3000 g of an extraction solvent (70% methanol) at 70 ° C for 3 hours. The extract was filtered through a filter having a pore size of 0.2 μm, concentrated, and dissolved in distilled water at 1:10 to prepare a rhubarb extract.
실시예Example 4: 4: 오수유Oh Suyu 추출물의 제조 Preparation of extract
오수유를 잘 건조하여 세절한 후, 건조 중량 100g을 플라스크에 넣고 추출 용매(70% 메탄올) 3000g으로 70℃에서 3시간동안 추출하였다. 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과, 농축한 후 증류수에 1:10으로 용해하여 오수유 추출물을 제조하였다.After drying and rinsing the sewage oil well, 100 g of dry weight was placed in a flask and extracted with 3000 g of an extraction solvent (70% methanol) at 70 ° C. for 3 hours. The extract was filtered through a filter having a pore size of 0.2 μm, concentrated, and dissolved in distilled water at 1:10 to prepare a sewage oil extract.
실시예Example 5: 5: 오필초Oh Pilcho 추출물의 제조 Preparation of extract
오필초를 잘 건조하여 세절한 후, 건조 중량 100g을 플라스크에 넣고 추출 용매(70% 메탄올) 3000g으로 70℃에서 3시간동안 추출하였다. 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과, 농축한 후 증류수에 1:10으로 용해하여 오필초 추출물을 제조하였다.After drying and rinsing off the well, 100 g of dry weight was placed in a flask and extracted with 3000 g of an extraction solvent (70% methanol) at 70 ° C for 3 hours. The extract was filtered through a filter having a pore size of 0.2 µm, concentrated, and dissolved in distilled water at 1:10 to prepare an Orfilacho extract.
실시예Example 6: 6: 향춘자Hyangchunja 추출물의 제조 Preparation of extract
향춘자를 잘 건조하여 세절한 후, 건조 중량 100g을 플라스크에 넣고 추출 용매(70% 메탄올) 3000g으로 70℃에서 3시간동안 추출하였다. 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과, 농축한 후 증류수에 1:10으로 용해하여 향춘자 추출물을 제조하였다.After drying and slicing Hyangchunja well, 100 g of dry weight was placed in a flask and extracted with 3000 g of an extraction solvent (70% methanol) at 70 ° C for 3 hours. The extract was filtered through a filter having a pore size of 0.2 μm, concentrated, and dissolved in distilled water at 1:10 to prepare a Hyangchunja extract.
실시예Example 7: 가와 추출물의 제조 7: Preparation of Kawa extract
가와를 잘 건조하여 세절한 후, 건조 중량 100g을 플라스크에 넣고 추출 용매(70% 메탄올) 3000g으로 70℃에서 3시간동안 추출하였다. 추출물을 0.2㎛의 기공 크기를 가진 필터로 여과, 농축한 후 증류수에 1:10으로 용해하여 가와 추출물을 제조하였다. After drying and crushing the Kawase well, 100 g of dry weight was placed in a flask and extracted with 3000 g of an extraction solvent (70% methanol) at 70 ° C for 3 hours. The extract was filtered through a filter having a pore size of 0.2 μm, concentrated, and dissolved in distilled water at 1:10 to prepare a Kawa extract.
실험예Experimental example 1: 자유라디칼 소거에 따른 항산화 효과 1: Antioxidant effect by free radical scavenging
실시예 1 내지 7에서 제조한 추출물의 항산화 효과를 확인하기 위하여, 1,1-디페닐-2-피크릴히드라질(1,1-diphenyl-2-picrylhydrazyl; DPPH) 방법으로 자유라디칼 소거능을 측정하였다(Blois, Nature 181, 1190, 1958). DPPH는 비교적 안정한 자유 라디칼로서 라디칼 상태로 존재시 517㎚에서 최대 흡광을 보이며 라디칼이 소거되면 흡광성을 잃는다. DPPH는 시그마(Sigma)사의 것을 사용하였으며, 0.15 mM의 농도로 메탄올에 녹여 사용하였다.To confirm the antioxidant effect of the extracts prepared in Examples 1 to 7, 1,1-diphenyl-2-picrylhydrazyl (1,1-diphenyl-2-picrylhydrazyl; DPPH) method to measure the free radical scavenging ability (Blois, Nature 181, 1190, 1958). DPPH is a relatively stable free radical that exhibits maximum absorption at 517 nm when present in a radical state and loses absorbance when the radical is eliminated. DPPH was used by Sigma, and dissolved in methanol at a concentration of 0.15 mM.
추출물 또는 양성대조군인 비타민 C를 96-웰 플레이트에 각각 100μl씩 넣고, DPPH 용액을 100μl씩 첨가하였다. 상온에서 30분간 방치하고 마이크로플레이트 리더(BioTek EL-340)를 이용하여 517㎚에서의 흡광도를 측정하였다. 시료를 처리한 것의 흡광도가 대조군의 흡광도의 절반이 될 때의 추출물의 농도(IC50)를 하기 표 1에 정리하였다. 실험은 3회 수행한 후 평균값을 계산하여 나타내었다. Vitamin C, an extract or a positive control, was added to each 96-well plate, and 100 μl of DPPH solution was added thereto. After standing at room temperature for 30 minutes, the absorbance at 517 nm was measured using a microplate reader (BioTek EL-340). The concentration of the extract (IC 50 ) when the absorbance of the sample treated is half the absorbance of the control group is summarized in Table 1 below. The experiment was performed three times, and the average value was calculated and presented.
상기 표 1에 나타낸 바와 같이, 실시예 1 내지 7 모두 각각 항산화 효과가 우수한 것을 확인하였다. 이를 통해, 몰식자, 소목, 대황, 오수유, 오필초, 향춘자 또는 가와 추출물은 모두 항산화 용도로 유용하게 사용될 수 있음을 알 수 있었다. As shown in Table 1, it was confirmed that each of Examples 1 to 7 had excellent antioxidant effects. Through this, it was found that all of the edible, bovine, rhubarb, osuyu, opilcho, hyangchunja or kawa extracts can be usefully used for antioxidant purposes.
실험예Experimental example 2: 2: 항당화Antiglycosylation 효과 effect
실시예 1 내지 7에서 제조한 추출물의 항당화 효과를 확인하기 위하여, L-아르기닌(L-arginine)과 포도당을 이용하여 당화 저해 활성을 측정하였다. In order to confirm the anti-glycosylation effect of the extracts prepared in Examples 1 to 7, L-arginine and glucose were used to measure glycosylation inhibitory activity.
먼저, 1M 인산 완충용액(pH 7.4)을 이용하여 1M L-아르기닌(arginine), 1M 포도당을 녹여 준비하고 1M 인산 완충용액을 이용하여 시료를 50ppm이 되도록 희석해서 준비하였다. 1M L-아르기닌과 1M 인산 완충용액을 1:4의 비율로 섞은 다음 96-웰 플레이트에 80 μl씩 분주하였다. 여기에 각각 50ppm으로 희석한 시료와 양성대조군으로 사용될 0.01M 아미노구아니딘(aminoguanidin)을 100 μl씩 첨가하였다. 잘 섞어준 다음, 포도당의 최종 농도가 0.1M이 되도록 1M 인산 완충용액으로 희석한 포도당을 넣은 후, 70℃에서 4시간 동안 반응시켰다. 96-웰 플레이트를 분광 광도계를 이용하여 420 nm에서 흡광도를 측정하여 당화 정도를 측정하였다.First, 1M L-arginine and 1M glucose were dissolved in 1M phosphate buffer solution (pH 7.4), and samples were diluted to 50 ppm using 1M phosphate buffer solution. 1M L-arginine and 1M phosphate buffer solution were mixed at a ratio of 1: 4, and then 80 μl was dispensed in a 96-well plate. To this, 100 μl of each sample diluted with 50 ppm and 0.01 M aminoguanidin to be used as a positive control were added. After mixing well, glucose diluted with 1 M phosphate buffer solution was added so that the final concentration of glucose was 0.1 M, followed by reaction at 70 ° C. for 4 hours. The 96-well plate was measured for absorbance by measuring the absorbance at 420 nm using a spectrophotometer.
하기 식의 Glycation 실험군은 1M L-아르기닌과 1M 포도당을 넣어 당화를 유발시킨 실험군이며, 시료 자체의 흡광도를 측정하기 위해서 포도당을 넣지 않고 1M L-아르기닌과 시료만을 넣어 420 nm에서 흡광도를 측정하였다. Glycation experimental group of the following formula is an experimental group inducing saccharification by adding 1M L-arginine and 1M glucose, and in order to measure the absorbance of the sample itself, absorbance was measured at 420 nm by adding only 1M L-arginine and a sample without adding glucose.
당화 저해율(%)은 하기 식을 이용하여 계산하였으며, 실험을 3회 수행한 후 평균값을 계산하여 표 2에 정리하였다.The glycation inhibition rate (%) was calculated using the following formula, and after performing the experiment three times, the average value was calculated and summarized in Table 2.
상기 표 2의 결과에서 볼 수 있듯이, 실시예 1 내지 7의 추출물은 모두 우수한 항당화 효과를 나타내었다. 이를 통해, 피부 보습, 피부 미백, 주름 개선, 피부 탄력 증진 등의 용도에 보조적인 역할로 작용하여 상승효과가 나타날 것임을 기대할 수 있다.As can be seen from the results of Table 2, the extracts of Examples 1 to 7 all exhibited excellent anti-glycosylation effects. Through this, it can be expected that a synergistic effect will be exhibited by acting as an auxiliary role in applications such as skin moisturizing, skin whitening, wrinkle improvement, and skin elasticity enhancement.
실험예Experimental example 3: 멜라닌 생성 억제에 따른 미백 효과 3: Whitening effect by suppressing melanin production
Lotan R. 외(Cancer Res. 40:3345-3350, 1980)에 기재된 방법에 따라, 쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 상기 추출물을 첨가하여 멜라닌 총량을 측정함으로써 미백 효과를 확인하였다. 실험 전 쥐의 멜라노마 세포에 대하여 독성을 평가하여 독성이 없는 농도를 선정하여 미백 평가를 수행하였다. 음성대조군으로는 DMSO를, 양성대조군으로는 알부틴(albutin)을 사용하였다. According to the method described in Lotan R. et al. (Cancer Res. 40: 3345-3350, 1980), the whitening effect is obtained by measuring the total amount of melanin by adding the extract to a culture medium of mouse melanoma cells (B-16 mouse melanoma cells). Was confirmed. Prior to the experiment, the whitening evaluation was performed by selecting the non-toxic concentration by evaluating the toxicity of the melanoma cells of the mouse. DMSO was used as a negative control, and albutin was used as a positive control.
구체적으로, 시료를 최종 농도가 100 ppm이 되도록 배지에 첨가하고, 알부틴은 100 ppm이 되도록 배지에 첨가한 후 멜라노마 세포를 3일간 배양하였다. 이후, 세포들을 트립신(trypsin) 처리하여 배양용기로부터 떼어내 원심분리한 후, 멜라닌을 추출하였다. 떼어낸 세포에 수산화나트륨 용액(1N 농도) 1 ml를 가하여 10분간 끓여 멜라닌을 녹이고, 분광 광도계를 이용하여 400 nm에서 흡광도를 측정하여 생성된 멜라닌의 양을 측정하였다. Specifically, the sample was added to the medium so that the final concentration was 100 ppm, and arbutin was added to the medium to be 100 ppm, and then melanoma cells were cultured for 3 days. Thereafter, cells were trypsin-treated, separated from the culture vessel, centrifuged, and melanin was extracted. 1 ml of sodium hydroxide solution (1N concentration) was added to the detached cells and boiled for 10 minutes to dissolve melanin, and the absorbance was measured at 400 nm using a spectrophotometer to measure the amount of melanin produced.
멜라닌 양은 단위 세포수 당(1×106 cell) 흡광도로 나타내는 방법으로 측정하였다. 대조군에 대한 상대적인 멜라닌 총량을 멜라닌 생성 저해율(%)로 계산하였으며, 실험을 3회 수행한 후 평균값을 계산하여 표 3에 정리하였다.The amount of melanin was measured by a method represented by absorbance per unit cell number (1 × 10 6 cells). The total amount of melanin relative to the control group was calculated as the rate of inhibition of melanin production (%), and the average value was calculated after performing the experiment three times and summarized in Table 3.
상기 표 3에서 알 수 있듯이, 실시예 1 내지 7의 추출물은 모두 저농도에서도 우수한 멜라닌 생성 저해효과가 나타났으며, 농도가 높을수록 그 효과가 뛰어남을 확인하였다. As can be seen from Table 3, the extracts of Examples 1 to 7 all exhibited excellent melanin production inhibitory effect even at low concentrations, and it was confirmed that the higher the concentration, the better the effect.
실험예Experimental example 4: NO 생성 억제에 따른 항염증 효과 4: Anti-inflammatory effect according to NO production inhibition
항염증 효과 및 피부트러블 개선 효과를 확인하기 위하여, RAW264.7 세포주 (ATCC number: CRL-2278)를 이용한 GRIESS법으로 나이트릭 옥사이드(nitric oxide; NO) 생성 억제능을 측정하였다.In order to confirm the anti-inflammatory effect and the improvement of skin trouble, the ability to inhibit nitric oxide (NO) production was measured by the GRIESS method using the RAW264.7 cell line (ATCC number: CRL-2278).
구체적으로, 생쥐의 대식세포인 RAW264.7 세포를 수차례 계대 배양하고, 웰 당 3×105개의 세포를 24-웰 프레이트에 넣은 후, 24시간 동안 배양하였다. 이어서, 최종농도 10ppm의 농도로 시료를 함유한 세포 배지로 교체하였다. 이때, NO 생성 억제물질인 L-NG-모노메틸아르기닌(L-NG-Monomethylarginine; L-NMMA)을 양성대조군으로 함께 처리하여 30분동안 배양하였고, 자극원으로 LPS(Lipopolysaccharide)를 1 ㎍씩 처리하여 24시간 동안 배양하였다. 상층액을 100 ㎕씩 취해 96-웰 프레이트에 옮기고, GRIESS 용액을 100 ㎕씩 가해 상온에서 10분동안 반응시킨 후, 540nm에서의 흡광도를 측정함으로써 NO 생성 저해 효과를 확인하였다.Specifically, RAW264.7 cells, which are macrophages of mice, were passaged several times, 3 × 10 5 cells per well were placed in a 24-well plate, and cultured for 24 hours. Subsequently, the sample was replaced with a cell medium containing a sample at a concentration of 10 ppm. At this time, L-NG-monomethylarginine (L-NMMA), an inhibitor of NO production, was treated together as a positive control group and cultured for 30 minutes, and 1 μg of LPS (Lipopolysaccharide) was treated as a stimulator. And cultured for 24 hours. After 100 μl of the supernatant was transferred to a 96-well plate, 100 μl of the GRIESS solution was added and reacted for 10 minutes at room temperature, and the effect of inhibiting NO production was confirmed by measuring absorbance at 540 nm.
NO 생성 저해율(%)은 하기 식을 이용하여 계산하였으며, 실험을 3회 수행한 후 평균값을 계산하여 표 4에 정리하였다.The inhibition rate of NO production (%) was calculated using the following formula, and the average value was calculated after performing the experiment three times and summarized in Table 4.
상기 표 4의 결과에서 알 수 있듯이, 실시예 1 내지 7의 추출물은 천연물질로서 우수한 항염증 활성을 나타냄을 확인하였다. 따라서, 피부 트러블 개선 용도로 사용할 수 있으며, 피부 미백, 주름 개선, 피부 탄력 증진, 피부 보습에 있어, 보조적인 역할로 작용하여 상승효과를 나타날 것을 기대할 수 있다.As can be seen from the results in Table 4, it was confirmed that the extracts of Examples 1 to 7 exhibit excellent anti-inflammatory activity as a natural material. Therefore, it can be used for skin trouble improvement, skin whitening, wrinkle improvement, skin elasticity enhancement, and skin moisturizing, it can be expected to show a synergistic effect by acting as an auxiliary role.
실험예Experimental example 5: 인체 유래의 섬유아세포에서 제1형 콜라겐(type Ⅰ collagen) 합성 촉진 효과 5: Effect of promoting the synthesis of type 1 collagen in fibroblasts derived from the human body
실시예 1 내지 7의 추출물을 인간 유래 섬유아세포의 배양액에 첨가하여 세포수준에서 제1형 콜라겐 합성 촉진 효과를 확인하였다. 합성된 콜라겐의 측정은 PICP EIA kit(Procollagen Type I C-Peptide Enzyme Immuno Assay KIT)를 이용하여 정량하였다. 콜라겐 합성량을 측정하기 위해 시료를 최종 농도가 10 ppm이 되도록 섬유아세포의 배양배지(DMEM 배지)에 첨가하여 48시간 동안 배양한 후 배양액을 취하여, PICP EIA 키트로 각 농도에서 제1형 콜라겐 합성 정도를 분광광도계를 이용하여 450 nm에서 측정하였다. The extracts of Examples 1 to 7 were added to the culture medium of human-derived fibroblasts to confirm the effect of promoting collagen type 1 synthesis at the cellular level. The measured collagen was quantified using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immuno Assay KIT). To measure the amount of collagen synthesis, the sample was added to the culture medium of fibroblasts (DMEM medium) so that the final concentration was 10 ppm, and then incubated for 48 hours, the culture solution was taken, and the collagen type 1 was synthesized at each concentration using the PICP EIA kit. The degree was measured at 450 nm using a spectrophotometer.
효과의 비교를 위하여 시료를 처리하지 않은 섬유아세포의 배양배지(음성대조군)와 비타민 C(양성대조군)를 최종농도 52.85 ㎍/ml가 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였다. In order to compare the effects, the degree of collagen synthesis was measured in the same manner for the samples in which the culture medium (negative control) and vitamin C (positive control) of untreated fibroblasts were added to a final concentration of 52.85 µg / ml.
콜라겐 생성 증가율(%)은 음성대조군에 대한 상대적인 콜라겐 생성량의 비율로 계산하였으며, 실험을 3회 수행한 후 평균값을 계산하여 표 5에 정리하였다.The increase rate of collagen production (%) was calculated as the ratio of the amount of collagen production relative to the negative control group. The average value was calculated after performing the experiment three times and summarized in Table 5.
상기 표 5에서 알 수 있듯이, 실시예 1 내지 7의 추출물은 모두 콜라겐 합성을 촉진시킴을 확인하였다. 또한, 농도가 높을수록 효과가 우수함을 알 수 있었다. As can be seen from Table 5, it was confirmed that the extracts of Examples 1 to 7 all promote collagen synthesis. In addition, it was found that the higher the concentration, the better the effect.
실험예Experimental example 6: 6: 엘라스타제Elastase 활성 저해 효과 Active inhibitory effect
엘라스틴(Elastin)을 분해하는 효소인 엘라스타제(Elastase)의 활성 저해 효과를 다음과 같이 확인하였다. 엘라스타제 사람의 백혈구 세포로부터 유래한 엘라스타제를 사용하였고, 기질로 합성 기질인 MeOSuc-Ala-Ala-Pro-Val-pNA를 사용하였다. 완충 용액은 100mM의 Tris(pH 7.5) 용액을 사용하였다. 엘라스타제는 완충용액을 이용하여 최종적으로 0.2 mU을 사용하였다. 또한 엘라스타제의 합성 기질은 DMSO를 이용하여 100mM 용액을 만든 후 최종 농도가 0.5mM이 되도록 완충용액을 이용하여 희석하였다. 이 때, 양성대조군은 엘라스타제 저해 물질로 알려진 쿼세틴(Quercetin)을 10ppm 농도로 넣은 것으로 설정하였다. 엘라스타제 저해 후보는 최종농도가 10ppm이 되도록 첨가하였다. 반응은 96-웰 플레이트에서 진행하였으며, 상온에서 20분동안 반응시켰다. The effect of inhibiting the activity of Elastase, an enzyme that breaks down Elastin, was confirmed as follows. Elastase Elastase derived from human leukocyte cells was used, and a synthetic substrate, MeOSuc-Ala-Ala-Pro-Val-pNA, was used. A buffer solution of 100 mM Tris (pH 7.5) was used. Elastase was finally used 0.2 mU using a buffer solution. In addition, the synthetic substrate of elastase was diluted with a buffer solution to make a final concentration of 0.5mM after preparing a 100mM solution using DMSO. In this case, the positive control group was set to contain 10 ppm of quercetin, known as an elastase inhibitor. Elastase inhibition candidates were added to a final concentration of 10 ppm. The reaction was carried out in a 96-well plate and reacted at room temperature for 20 minutes.
분광광도계를 이용하여 1분 간격으로 405 nm에서 흡광도를 측정하여, 시간 대비 흡광도의 기울기를 구하여 효소의 활성도로 정하였다. 엘라스타제 저해율(%)은 하기 식을 이용하여 계산하였으며, 실험을 3회 수행한 후 평균값을 계산하여 표 6에 정리하였다.The absorbance was measured at 405 nm at 1 minute intervals using a spectrophotometer, and the slope of the absorbance versus time was determined to determine the activity of the enzyme. The elastase inhibition rate (%) was calculated using the following formula, and the average value was calculated after performing the experiment three times and summarized in Table 6.
상기 표 6의 결과와 같이, 실시예 1 내지 7의 추출물은 모두 엘라스타제 활성 저해 효과가 뛰어남을 확인하였다. 즉, 피부 재생, 주름 개선, 피부 탄력 증진을 위한 용도로 사용할 수 있음을 알 수 있었다. As shown in Table 6, it was confirmed that the extracts of Examples 1 to 7 were all excellent in inhibiting the elastase activity. That is, it was found that it can be used for skin regeneration, wrinkle improvement, and skin elasticity.
실험예Experimental example 7: 세포 증식에 따른 피부 재생 효과 7: Skin regeneration effect by cell proliferation
실시예 1 내지 7의 추출물의 세포 증식 효과는 다음과 같은 방법으로 실험하였다. 사람의 섬유아세포(human fibroblast cell)를 96-웰 플레이트(96 well plate, Corning사)에 접종하여 배양한 다음, 실시예 1 내지 7을 1%의 농도로 2일 동안 적용하고, MTT 시험 방법을 수행하여 세포증식을 평가하였다. 보다 구체적으로, 인간 섬유아세포를 24-웰 플레이트에 웰 당 5×103개씩 동일하게 hemocytometer를 이용하여 계수한 후 분주하였다. 10% FBS를 함유하는 DMEM에서 48시간 배양하여 배양용기 표면적의 40 ~ 50%만큼 배양되면, 시료를 FBS-free DMEM으로 교체하여 24시간 더 배양하였다. 배양 후 3-(4,5-디메틸싸이아졸-2-일)-2,5-디페닐테트라 졸륨 브로마이드[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT; Sigma M5655, USA] 용액 (2.5 mg/ml)을 50 ul 첨가하고 3시간 추가로 배양하였다. 그 후, 세포 배양액을 전부 버리고, 200 ul의 디메틸 설폭사이드(dimethyl sulfoxide, DMSO; Sigma D2650, USA)를 각 웰 당 200ul씩 처리하여 교반한 후, 100 ul씩을 96 well로 취하여 Enzyme-Linked Immunosorbent Assay(ELISA)로 570nm에서 흡광도를 측정하였다. 대조군으로는 무혈청 배지를 사용하였으며, 비교군으로는 혈청 1%를 부가하여 사용하였다. 실험을 3회 수행한 후 평균값을 계산하여 표 7에 정리하였다.The cell proliferation effect of the extracts of Examples 1 to 7 was tested by the following method. Human fibroblast cells (human fibroblast cells) were inoculated in a 96-well plate (96 well plate, Corning), cultured, and then applied to Examples 1 to 7 at a concentration of 1% for 2 days Cell proliferation was evaluated. More specifically, human fibroblasts were counted and distributed using a hemocytometer equal to 5 × 10 3 cells per well in a 24-well plate. When cultured in DMEM containing 10% FBS for 48 hours, and incubated for 40-50% of the surface area of the culture vessel, the sample was replaced with FBS-free DMEM and further cultured for 24 hours. 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide after culture (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide, MTT ; Sigma M5655, USA] 50 ul of solution (2.5 mg / ml) was added and incubated for an additional 3 hours. After that, the cell culture solution was completely discarded, and 200 ul of dimethyl sulfoxide (DMSO; Sigma D2650, USA) was treated and stirred for 200 ul per well, and 100 ul of each was taken as 96 wells to take Enzyme-Linked Immunosorbent Assay. Absorbance at 570 nm was measured by (ELISA). Serum-free medium was used as a control, and 1% of serum was added as a control group. After performing the experiment three times, the average value was calculated and summarized in Table 7.
상기 표 7의 결과와 같이, 실시예 1 내지 7 모두 세포 증식을 촉진시키는 효과가 있어 피부 재생 용도로 사용할 수 있음을 알 수 있었다. As shown in Table 7, it was found that all of Examples 1 to 7 have an effect of promoting cell proliferation and can be used for skin regeneration.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will appreciate that the present invention may be implemented in other specific forms without changing its technical spirit or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be construed as including all changes or modifications derived from the meaning and scope of the following claims rather than the detailed description and equivalent concepts thereof.
Claims (14)
A cosmetic composition comprising as an active ingredient, edible, bovine, rhubarb, osuyu, opilcho, hyangchunja or Kawa extract.
The cosmetic composition according to claim 1, wherein the composition is for antioxidant.
The cosmetic composition according to claim 1, wherein the composition is for moisturizing the skin.
According to claim 1, The composition is for skin whitening, cosmetic composition.
The cosmetic composition according to claim 1, wherein the composition is for improving skin trouble.
According to claim 1, The composition is for improving wrinkles, cosmetic composition.
The cosmetic composition according to claim 1, wherein the composition is for enhancing skin elasticity.
The cosmetic composition according to claim 1, wherein the composition is for skin regeneration.
The cosmetic composition according to any one of claims 1 to 8, wherein the composition has anti-glycosylation, melanin reduction, collagen synthesis promotion, elastase activity inhibition, or cell proliferation effect.
The composition according to any one of claims 1 to 8, wherein the composition is a solution, external ointment, cream, foam, nutrient makeup, softening makeup, pack, softening water, emulsion, makeup base, essence, soap, liquid detergent, bathing agent , Sunscreen cream, sun oil, suspension, emulsion, paste, gel, lotion, powder, soap, surfactant-containing cleaning, oil, powder foundation, emulsion foundation, wax foundation, patch and spray The cosmetic composition having a formulation.
Food composition comprising as an active ingredient, edible, bovine, rhubarb, osuyu, opilcho, hyangchunja or Kawa extract.
The composition of claim 11, wherein the composition is for antioxidant; For skin moisturizing; For skin whitening; For improving skin problems; Wrinkle improvement; For skin elasticity enhancement; Or for skin regeneration, food composition.
A quasi-drug composition comprising as an active ingredient, edible, bovine, rhubarb, osuyu, opilcho, hyangchunja or kawa extract.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180117818A KR102158780B1 (en) | 2018-10-02 | 2018-10-02 | Composition for improving skin comprising natural material extract |
PCT/KR2019/009888 WO2020071630A1 (en) | 2018-10-02 | 2019-08-07 | Composition for improving skin comprising extracts of natural products |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180117818A KR102158780B1 (en) | 2018-10-02 | 2018-10-02 | Composition for improving skin comprising natural material extract |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200119183A Division KR20200110291A (en) | 2020-09-16 | 2020-09-16 | Composition for improving skin comprising natural material extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20200038115A true KR20200038115A (en) | 2020-04-10 |
KR102158780B1 KR102158780B1 (en) | 2020-09-22 |
Family
ID=70055282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180117818A KR102158780B1 (en) | 2018-10-02 | 2018-10-02 | Composition for improving skin comprising natural material extract |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102158780B1 (en) |
WO (1) | WO2020071630A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220107545A (en) * | 2021-01-25 | 2022-08-02 | (주)셀아이콘랩 | NEW COSMETICS COMPOSITION FOR INHIBITING MELANIN PIGMENT PRODUCTION WITH BOTH α-MSH COMPETITIVE EFFECT AND TYROSINASE INHIBITION EFFECT |
KR20220107803A (en) | 2021-01-26 | 2022-08-02 | 한국한의약진흥원 | Cosmetic composition for skin improvement with antioxidizing, whitening and antiwrinkle effect comprising 3-Deoxysappanone B |
KR20230103387A (en) | 2021-12-31 | 2023-07-07 | 대전대학교 산학협력단 | Anti-oxidant, anti-pruritic, skin whitening composition comprising Artemisia argyi H. extract |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000319154A (en) * | 1999-05-06 | 2000-11-21 | Nippon Menaade Keshohin Kk | Phototoxicity inhibitor |
JP2005162651A (en) * | 2003-12-02 | 2005-06-23 | Ichimaru Pharcos Co Ltd | Demelanizing agent |
JP2011006462A (en) * | 2010-08-26 | 2011-01-13 | Ichimaru Pharcos Co Ltd | Tyrosinase activity inhibitor |
KR101952695B1 (en) * | 2017-10-19 | 2019-02-27 | 주식회사 익스플즌 | Composition having anti-wrinkle effects using the natural plant extract and cosmetic composition comprising the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100328975B1 (en) * | 1999-09-03 | 2002-03-20 | 서경배 | Whitening composition including the myrrh extract |
KR20040059007A (en) * | 2002-12-27 | 2004-07-05 | 주식회사 엘지생활건강 | Skin Whitening Cosmetic containing a herb extract with inhibitory activity of melanin formation |
KR101220903B1 (en) * | 2005-07-18 | 2013-01-11 | 주식회사 엘지생활건강 | Composition of skin external for improving of skin wrinkle |
US20080175934A1 (en) * | 2006-12-29 | 2008-07-24 | Himalaya Global Holdings Limited | Novel herbal composition of extracts of quercus infectoria, process for preparing the same and use thereof |
KR20110094859A (en) * | 2010-02-18 | 2011-08-24 | 웅진코웨이주식회사 | Composition for promoting collagen synthesis having kava extract |
KR101533624B1 (en) * | 2013-06-25 | 2015-07-07 | 한국콜마주식회사 | A Cosmetic Composition Containing Extracts of Potentilla kleiniana Wight et Arnott Having antibacterial Activity |
KR101946880B1 (en) * | 2017-01-31 | 2019-02-12 | 세명대학교 산학협력단 | Composition for improving skin barrier function and skin moisturizing agent comprising an extract of Caesalpinia sappn L. |
-
2018
- 2018-10-02 KR KR1020180117818A patent/KR102158780B1/en active IP Right Grant
-
2019
- 2019-08-07 WO PCT/KR2019/009888 patent/WO2020071630A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000319154A (en) * | 1999-05-06 | 2000-11-21 | Nippon Menaade Keshohin Kk | Phototoxicity inhibitor |
JP2005162651A (en) * | 2003-12-02 | 2005-06-23 | Ichimaru Pharcos Co Ltd | Demelanizing agent |
JP2011006462A (en) * | 2010-08-26 | 2011-01-13 | Ichimaru Pharcos Co Ltd | Tyrosinase activity inhibitor |
KR101952695B1 (en) * | 2017-10-19 | 2019-02-27 | 주식회사 익스플즌 | Composition having anti-wrinkle effects using the natural plant extract and cosmetic composition comprising the same |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220107545A (en) * | 2021-01-25 | 2022-08-02 | (주)셀아이콘랩 | NEW COSMETICS COMPOSITION FOR INHIBITING MELANIN PIGMENT PRODUCTION WITH BOTH α-MSH COMPETITIVE EFFECT AND TYROSINASE INHIBITION EFFECT |
KR20220107803A (en) | 2021-01-26 | 2022-08-02 | 한국한의약진흥원 | Cosmetic composition for skin improvement with antioxidizing, whitening and antiwrinkle effect comprising 3-Deoxysappanone B |
KR20230103387A (en) | 2021-12-31 | 2023-07-07 | 대전대학교 산학협력단 | Anti-oxidant, anti-pruritic, skin whitening composition comprising Artemisia argyi H. extract |
Also Published As
Publication number | Publication date |
---|---|
KR102158780B1 (en) | 2020-09-22 |
WO2020071630A1 (en) | 2020-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101819727B1 (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
KR101971837B1 (en) | Cosmetic composition for improving skin whitening and wrinkle comprising adventitious root extract of Centella asiatica as effective component | |
KR102158780B1 (en) | Composition for improving skin comprising natural material extract | |
KR102022622B1 (en) | Composition for improving skin conditions comprising panax ginseng sprout extract or fraction thereof and method for improving skin conditions using the same | |
JP2006199678A (en) | Skin cosmetic and food/drink for cosmetrogical use | |
KR20080049352A (en) | Cosmetic composition containing tilianin or acacetin | |
US20200078290A1 (en) | Cosmetic Composition Comprising Extract Of Medicinal Herbs As Active Ingredient | |
KR20140086747A (en) | Health Functional Food Composition Comprising Red Ginseng Extract, Benincasa Hispida Extract, and Apios Americana Extract for Improving Skin Beauty | |
KR102425559B1 (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
KR20170136389A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102639155B1 (en) | Composition for skin improvement containing valechlorine | |
KR20150145704A (en) | Composition comprising extract of autumn soybean-leaves | |
KR102629000B1 (en) | Composition for skin improvement containing Salvianolic acid C | |
KR101182765B1 (en) | Cosmetic Composition Comprising Citrus sunkiSanmul S.Marcov And Zingiber Officinale Roscoe Mixed Extract Having Anti-oxidation and Anti-aging Effects And Manufacturing Method Thereof | |
KR102462347B1 (en) | Cosmetic composition for improving skin barrier function and anti-wrinkle effects comprising fermented eggplant extract as an active ingredient | |
KR102471009B1 (en) | Cosmetic composition containing Albiggia kalkora extract for skin whitening and improving wrinkles | |
KR20140089305A (en) | Composition for improving skin whitening or skin wrinkle comprising extracts of Quercus salicina Blume | |
KR20120081289A (en) | A skin-care agent containing fermented licorice extracts | |
KR102244585B1 (en) | Complex cosmetic composition for improving skin-aging | |
KR101924446B1 (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
KR101695372B1 (en) | Composition for improving wrinkle and elasticity containing ribes nigrum extracts | |
KR20170137560A (en) | Composition for improving skin condition comprising herb extracts mixture | |
KR102183896B1 (en) | Composition for improving skin | |
KR20200110291A (en) | Composition for improving skin comprising natural material extract | |
KR102534239B1 (en) | Cosmetic composition comprising glutathione, Maqui Berry extract and Mulberry root extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
A107 | Divisional application of patent | ||
GRNT | Written decision to grant |